Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study

Inflammatory Bowel Diseases

Volumn 16, Issue 9, 2010, Pages 1575-1582

  Ito, Hiroaki ^a   Iida, Mitsuo ^b   Matsumoto, Takayuki ^c   Suzuki, Yasuo ^d   Aida, Yoshiyuki ^e   Yoshida, Toyomitsu ^e   Takano, Yuichi ^e   Hibi, Toshifumi ^f  

^a Kitano Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^e ZERIA PHARMACEUTICAL CO LTD   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colonoscopy; Mesalamine; Randomized controlled trial; Ulcerative colitis

Indexed keywords

ETHYL CELLULOSE; EUDRAGIT; MESALAZINE;

ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; HEMATOCHEZIA; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE COUNT; MULTICENTER STUDY; OUTCOME ASSESSMENT; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; TIMED DRUG RELEASE; TREATMENT DURATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MESALAMINE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954414147     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21194     Document Type: Article

References (17)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385. (Pubitemid 39062279)
2. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):1-16.
3. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:354-356.
4. Van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578. (Pubitemid 41531774)
5. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196-200. (Pubitemid 17027391)
6. Mardini HA, Lindsay DC, Deighton CM, et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987;28:1084-1089.
7. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989;38:500-523.
8. Sinha A, Ball DJ, Connor AL, et al. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol. 2003;27:56-69. (Pubitemid 37362992)
9. Riley SA, Tavares IA, Bennett A, et al. Delayed-release mesalamine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol. 1988;26:173-177.
10. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898. (Pubitemid 17072238)
11. Mahadevan U, Tremaine WJ, Johnson T, et al. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol. 2000;95:3463-3468.
12. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
13. Hanauer SB, Sinsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. Ann Intern Med. 1996;124:204-211.
14. Miner P, Hanauer S, Robinson M, et al. Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci. 1995;40:296-304.
15. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001;7:221-225. (Pubitemid 32776515)
16. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89-92.
17. Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol. 2008;1:40-45.